Medlab Clinical Ltd (ASX:MDC), an Australian biotech using delivery platforms to enhance medicines is pleased to announce the execution of a Master Services Agreement with WEP Clinical Ltd for the exclusive development and delivery of Named Patient Programmes
BTC Health Limited (ASX:BTC) Acquires Exclusive Distribution Rights for Bronchitol(R) and Aridol(R) from Pharmaxis
BTC Health Limited (ASX:BTC) is pleased to announce its investee company, BioImpact Pty Ltd, has acquired exclusive distribution rights for specialty respiratory brands Bronchitol(R) and Aridol(R) from Pharmaxis (ASX:PXS) in Australia, New Zealand, Singapore, Malaysia, Hong Kong and South Korea (Bronchitol(R) only).
BTC Health Limited (ASX:BTC) $2.5m Capital Raise to Acquire the Distribution Rights to Bronchitol(R) and Aridol(R)
BTC Health Limited (ASX:BTC) is pleased to announce the receipt of binding firm commitments for a $2.5 million private placement to fund the acquisition of exclusive distribution rights to Bronchitol(R) and Aridol(R) in Australia, New Zealand, Malaysia, Hong Kong and Singapore.
IRIS Teams up with DIAGNOS Inc (CVE:ADK) in a Multi-Year Agreement to Implement Artificial Intelligence Technology with Support From the INVEST-AI Program
Diagnos Inc. (CVE:ADK) (OTCMKTS:DGNOF) (4D4A.F), a leader in early detection of critical health issues, is pleased to announce the signing of a multi-year agreement with IRIS The Visual Group (1990) Inc.
DIAGNOS (CVE:ADK) Enters into Exclusive Distribution Agreement to Access Massive Global Healthcare Market in DACH Countries and Central Europe of Over 140 Million People
Diagnos Inc. (CVE:ADK) (OTCMKTS:DGNOF) (FRA:4D4A), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today the signing of an exclusive distribution agreement with Diagnos Europe GmbH.
Cortical is an Australian based medical device technology company that has developed an industry disruptive brain function monitor independently described as "a paradigm busting technology from an Australian based device house that really gives a significant advantage in this space".
Cann Global continued to drive sales throughout the quarter resulting in cash receipts from customers of $333k up 54.6% on the prior corresponding period, but lower than the prior quarter due to shipping delays and therefore delayed payment on contracted sales.
Cann Global Limited (ASX:CGB) is pleased to confirm that the 1 for 4 renounceable entitlement offer announced on 3 July 2020 (Entitlement Offer), closed on Thursday 23 July 2020.
Cann Global Ltd (ASX:CGB) today confirms that its Directors and largest shareholders intend to participate in the rights issues announced on 3 July 2020.
Cann Global Limited's (ASX:CGB) medical Cannabis research division, Medical Cannabis Research Group Pty Ltd (MCRG) entered into a research agreement to research the possibility of the use of cannabis in the treatment of autoimmune disease, specifically multiple sclerosis (MS).
Banking & Finance
- NSX Limited (ASX:NSX) Direct Retail Online Market Access via Marketech
- NSX Ltd (ASX:NSX) Quarterly Activities Report
- Asset Resolution Limited (NSX:ASS) NobleOak Investment Update
Oil Gas & Energy
- State Gas Limited (ASX:GAS) Quarterly Activities Report
- Central Petroleum Limited (ASX:CTP) Quarterly Activities Report
- Empire Energy Group Ltd (ASX:EEG) Quarterly Activities Report